Accelerated Phase Chronic Myeloid Leukemia and Treatment Free Remission Maintained After Five Years of Nilotinib: A Case Report.
accelerated phase
chronic myeloid leukemia
nilotinib
treatment free remission
tyrosine kinase inhibitor
Journal
Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867
Informations de publication
Date de publication:
2021
2021
Historique:
received:
16
04
2021
accepted:
19
05
2021
entrez:
28
6
2021
pubmed:
29
6
2021
medline:
29
6
2021
Statut:
epublish
Résumé
The present article reports the case of a patient presenting with chronic myeloid leukemia, diagnosed during the accelerated phase (>20% blasts in peripheral blood samples and megakaryocyte agglomerates in the bone marrow). The subject was treated with first-line therapy with the tyrosine kinase inhibitor nilotinib and reached complete clinical and molecular remission (according to the European Leukemia Net-ELN-criteria), which persisted over five years of treatment. Five years after discontinuation of nilotinib (ten years from diagnosis), the patient is in good clinical condition, with no traces of BCL-ABL1 at molecular evaluation (molecular response, MR
Identifiants
pubmed: 34178695
doi: 10.3389/fonc.2021.696253
pmc: PMC8226074
doi:
Types de publication
Case Reports
Langues
eng
Pagination
696253Informations de copyright
Copyright © 2021 Capodanno, Lugli, Codeluppi, Faruolo, Bellesia, Valli and Merli.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Leukemia. 2017 Apr;31(4):1015-1016
pubmed: 28093565
Leukemia. 2020 Apr;34(4):966-984
pubmed: 32127639
Ann Oncol. 2017 Jul 1;28(suppl_4):iv41-iv51
pubmed: 28881915
Lancet. 2007 Jul 28;370(9584):342-50
pubmed: 17662883
J Clin Oncol. 2017 Jan 20;35(3):298-305
pubmed: 28095277
J Clin Oncol. 2014 Feb 10;32(5):424-30
pubmed: 24323036
Leukemia. 2017 Jul;31(7):1525-1531
pubmed: 28218239
Blood. 2013 Aug 8;122(6):872-84
pubmed: 23803709
Lancet Oncol. 2010 Nov;11(11):1029-35
pubmed: 20965785
J Clin Oncol. 2016 Aug 20;34(24):2851-7
pubmed: 27325849
Blood. 2013 Jul 25;122(4):515-22
pubmed: 23704092
Am J Hematol. 2015 Oct;90(10):910-4
pubmed: 26178642
N Engl J Med. 2010 Jun 17;362(24):2251-9
pubmed: 20525993
J Natl Compr Canc Netw. 2020 Oct 01;18(10):1385-1415
pubmed: 33022644
Leukemia. 2016 Aug;30(8):1638-47
pubmed: 27133824
Lancet Oncol. 2018 Jun;19(6):747-757
pubmed: 29735299
Am J Hematol. 2020 Jun 17;:
pubmed: 32557828
Blood Adv. 2019 Dec 23;3(24):4280-4290
pubmed: 31869412
Blood. 2017 Feb 16;129(7):846-854
pubmed: 27932374
Bioorg Med Chem. 2010 Oct 1;18(19):6977-86
pubmed: 20817538
Cancer. 2017 Nov 15;123(22):4403-4410
pubmed: 28743166
Haematologica. 2018 Nov;103(11):1835-1842
pubmed: 29976734
Cancer. 2018 Jul 15;124(14):2956-2963
pubmed: 29723417